CD3E and neoplasm: Simultaneous binding of cibisatamab to CEA and CD3ε causes T-cell activation independent of T-cell receptor specificity, leading to lymphocyte-mediated tumour cell killing, immune-stimulatory cytokine release and further release of tumour antigens.